Assessing the minimal important difference in symptoms: A comparison of two techniques

Journal of Clinical Epidemiology

Volumn 49, Issue 11, 1996, Pages 1215-1219

  Redelmeier, Donald A ^a,b   Guyatt, Gordon H ^c   Goldstein, Roger S ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d WEST PARK HEALTHCARE CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DECISION MAKING; DYSPNEA; FEMALE; HEALTH STATUS; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; SYMPTOMATOLOGY;

ADAPTATION, PSYCHOLOGICAL; AGED; DYSPNEA; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HEALTH STATUS INDICATORS; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MALE; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS;

EID: 0030298527     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(96)00206-5     Document Type: Article

References (15)

1. 1. Feinstein AR. Clinical Epidemiology: The Architecture of Clinical Research. Philadelphia: W. B. Saunders; 1985: 396-400.
2. 2. Guyatt GH, Feeny D, Patrick D. Proceedings ot the international conference on the measurement of quality of life as an outcome in clinical trials: Postscript. Controlled Clin Trials 1991; 12: 266S-269S.
3. 3. Detsky AS, Sackett DL. When was a "negative" clinical trial big enough? How many patients you needed depends on what you found. Arch Intern Med 1985; 145: 709-712.
4. 4. Burnand B, Kernant WN, Feinstein AR. Indexes and boundaries for "quantitative significance" in statistical decisions. J Clin Epidemiol 1990; 43:1273-1284.
5. 5. Redelmeier DA, Lorig K. Assessing the clinical importance of symptomatic improvements. Arch Intern Med 1993; 153: 1337-1342.
6. 6. Wells GA, Tugwell P, Kraag GR, Baker P, Groh J, Redelmeier DA. Minimum important differences between patients with rheumatoid arthritis: The patient's perspective. J Rheumatol 1993; 20: 557-560.
7. 7. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42: 773-778.
8. 8. Jaeschke R, Singer J, Guyatt GH. Measurements of health status: Ascertaining the minimally clinically important difference. Controlled Clin Trials 1989; 10: 407-415.
9. 9. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life instrument. J Clin Epidemiol 1994; 47: 81-87.
10. 10. Guyatt GH, Townsend M, Keller JL, et al. Measuring functional status in chronic lung disease: Conclusions from a randomized control trial. Resp Med 1989; 83: 293-297.
11. 11. Guyatt GH, Townsend M, Pugsley SO, et al. Bronchodilators in chronic airflow limitation: Effects on airway function, exercise capacity, and quality of life. Am Rev Resp Dis 1987; 135: 1069-1074.
12. 12. Llewellyn-Thomas HA, Naylor CD, Cohen MM, Basinski ASH, Ferris LE, Williams JI. Studying patients' preferences in health care decision making. Can Med Assoc J 1992; 147: 859-864.
13. 13. Taylor SE, Brown JD. Illusion and well-being: A social psychological perspective on mental health. Psychol Bull 1988; 103: 193-210.
14. 14. Guyatt GH, Feeny D, Patrick D. Measuring health-related quality of life. Ann Intern Med 1993; 118: 622-629.
15. 15. Naylor CD, Llewellyn-Thomas HA. Can there be a more patient-centred approach to determining clinically important effect sizes for randomized treatment trials? J Clin Epidemiol 1994; 47: 787-795.